These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 24361481)

  • 1. Evaluation of reverse phase protein array (RPPA)-based pathway-activation profiling in 84 non-small cell lung cancer (NSCLC) cell lines as platform for cancer proteomics and biomarker discovery.
    Ummanni R; Mannsperger HA; Sonntag J; Oswald M; Sharma AK; König R; Korf U
    Biochim Biophys Acta; 2014 May; 1844(5):950-9. PubMed ID: 24361481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular predictors of sensitivity to the MET inhibitor PHA665752 in lung carcinoma cells.
    Matsubara D; Ishikawa S; Oguni S; Aburatani H; Fukayama M; Niki T
    J Thorac Oncol; 2010 Sep; 5(9):1317-24. PubMed ID: 20736805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence.
    Nanjundan M; Byers LA; Carey MS; Siwak DR; Raso MG; Diao L; Wang J; Coombes KR; Roth JA; Mills GB; Wistuba II; Minna JD; Heymach JV
    J Thorac Oncol; 2010 Dec; 5(12):1894-904. PubMed ID: 21124077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Signaling pathway profiling by reverse-phase protein array for personalized cancer medicine.
    Masuda M; Yamada T
    Biochim Biophys Acta; 2015 Jun; 1854(6):651-7. PubMed ID: 25448010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variable apoptotic response of NSCLC cells to inhibition of the MEK/ERK pathway by small molecules or dominant negative mutants.
    Brognard J; Dennis PA
    Cell Death Differ; 2002 Sep; 9(9):893-904. PubMed ID: 12181740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
    Li H; Schmid-Bindert G; Wang D; Zhao Y; Yang X; Su B; Zhou C
    Adv Med Sci; 2011; 56(2):275-84. PubMed ID: 22037177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein pathway activation mapping of brain metastasis from lung and breast cancers reveals organ type specific drug target activation.
    Improta G; Zupa A; Fillmore H; Deng J; Aieta M; Musto P; Liotta LA; Broaddus W; Petricoin EF; Wulfkuhle JD
    J Proteome Res; 2011 Jul; 10(7):3089-97. PubMed ID: 21574647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
    Gadgeel SM; Wozniak A
    Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential expression and activation of epidermal growth factor receptor 1 (EGFR1), ERK, AKT, STAT3, and TWIST1 in nonsmall cell lung cancer (NSCLC).
    Gorgisen G; Ozes D; Pehlivanoglu S; Erdogan A; Dertsiz L; Ozbilim G; Ozbudak IH; Savas B; Ozes ON
    Exp Lung Res; 2013 Nov; 39(9):387-98. PubMed ID: 24117170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reverse phase protein arrays in signaling pathways: a data integration perspective.
    Creighton CJ; Huang S
    Drug Des Devel Ther; 2015; 9():3519-27. PubMed ID: 26185419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells.
    Han SY; Zhao MB; Zhuang GB; Li PP
    Lung Cancer; 2012 Jan; 75(1):30-7. PubMed ID: 21757251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells.
    Janmaat ML; Rodriguez JA; Gallegos-Ruiz M; Kruyt FA; Giaccone G
    Int J Cancer; 2006 Jan; 118(1):209-14. PubMed ID: 16003751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced expression of EI24 confers resistance to gefitinib through IGF-1R signaling in PC9 NSCLC cells.
    Choi JM; Jang JY; Choi YR; Kim HR; Cho BC; Lee HW
    Lung Cancer; 2015 Nov; 90(2):175-81. PubMed ID: 26342551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative proteomic approach to understand metabolic adaptation in non-small cell lung cancer.
    Martín-Bernabé A; Cortés R; Lehmann SG; Seve M; Cascante M; Bourgoin-Voillard S
    J Proteome Res; 2014 Nov; 13(11):4695-704. PubMed ID: 25029028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
    Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
    Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.
    Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N
    Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic classification of the RAS network identifies a personalized treatment strategy for lung cancer.
    El-Chaar NN; Piccolo SR; Boucher KM; Cohen AL; Chang JT; Moos PJ; Bild AH
    Mol Oncol; 2014 Oct; 8(7):1339-54. PubMed ID: 24908424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation.
    Noro R; Gemma A; Kosaihira S; Kokubo Y; Chen M; Seike M; Kataoka K; Matsuda K; Okano T; Minegishi Y; Yoshimura A; Kudoh S
    BMC Cancer; 2006 Dec; 6():277. PubMed ID: 17150102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.
    Ishii H; Azuma K; Sakai K; Kawahara A; Yamada K; Tokito T; Okamoto I; Nishio K; Hoshino T
    Oncotarget; 2015 Oct; 6(31):30850-8. PubMed ID: 26334838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer.
    Ota K; Azuma K; Kawahara A; Hattori S; Iwama E; Tanizaki J; Harada T; Matsumoto K; Takayama K; Takamori S; Kage M; Hoshino T; Nakanishi Y; Okamoto I
    Clin Cancer Res; 2015 Sep; 21(17):4014-21. PubMed ID: 26019170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.